SynthesisBiomolecules & biomedicine2025
Influence of maternal diabetes during pregnancy on ultrasound-measured fetal epicardial fat thickness: A meta-analysis.
Synthesis in Biomolecules & biomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The association between gestational diabetes mellitus and cancer in women: an updated systematic review and meta-analysis.Journal of diabetes and metabolic disorders · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maternal diabetes during pregnancy, including gestational diabetes mellitus (GDM) and pregestational diabetes mellitus (PDM), has been linked to alterations in fetal development. This meta-analysis aimed to investigate the impact of maternal diabetes on fetal epicardial fat thickness (fEFT), measured via ultrasound-a potential marker of cardiometabolic risk. A systematic search of PubMed, Embase, and Web of Science was conducted to identify observational studies assessing fEFT in pregnant women with and without diabetes. A random-effects model was used to calculate the mean difference (MD) in fEFT between groups. Heterogeneity was evaluated using the I² statistic, and sensitivity, subgroup, and meta-regression analyses were performed to explore sources of variability. Data from 10 studies, comprising 12 datasets and 1303 participants, were pooled. Women with diabetes during pregnancy had significantly higher fEFT compared to those without diabetes (MD: 0.37 mm, 95% confidence interval [CI]: 0.26 to 0.49, P < 0.001), with moderate heterogeneity (I² = 69%). Sensitivity analyses, conducted by excluding one dataset at a time, confirmed the robustness of the findings (all P values < 0.05). Meta-regression revealed a positive correlation between gestational age (GA) at fEFT measurement and fEFT differences (coefficient = 0.040, P = 0.005), accounting for 83.2% of the heterogeneity. Subgroup analyses demonstrated consistent results across study designs, maternal diabetes types, and demographic factors but highlighted greater fEFT differences in studies where GA at fEFT measurement was >26 weeks. In conclusion, maternal diabetes during pregnancy is associated with increased fEFT, particularly in later gestation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.